<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03407859</url>
  </required_header>
  <id_info>
    <org_study_id>2016-XYNK-002</org_study_id>
    <nct_id>NCT03407859</nct_id>
  </id_info>
  <brief_title>Sequential Treatment With CD20/CD22/CD10-CART After CD19-CART Treatment Base on MRD in Relapsed/Refractory B-ALL</brief_title>
  <official_title>Sequential Treatment With CD20/CD22/CD10-CART After CD19-CART Treatment Base on MRD in Relapsed/Refractory B-ALL</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhujiang Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Nanfang Hospital of Southern Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Zhujiang Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      CD19-negative B-ALL relapses after CD19 CAR T-cell treatment have occurred in some patients.&#xD;
      CD20/CD22/CD10 is still expressed in CD19 negative B-ALL cells which means these CD molecules&#xD;
      may become new targets in treatment of CD19-negative relapse of B-ALL. Thus sequential&#xD;
      treatment with CD20/CD22/CD10-CART after CD19-CART treatment in relapsed/refractory B-ALL&#xD;
      will kill and eliminate CD19 negative B-ALL cells and prolong the remission time.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      B-cell acute lymphoblastic leukemia is the most common type of leukemia and the prognosis of&#xD;
      relapsed/refractory B-ALL is poor. Chimeric Antigen Receptor-transduced T cell (CAR-T)&#xD;
      therapy is one of revolutionary targeted immunotherapy. CD19 CAR-T is the most commonly used&#xD;
      engineered T cell in B-ALL. The treatment effect is significant and far more than traditional&#xD;
      therapy in relapsed/refractory B-ALL. However, the remission time after CD19 CAR-T infusion&#xD;
      is short.CD19-positive and CD19-negative B-ALL relapses after CD19 CAR T-cell treatment have&#xD;
      occurred in some patients The cause of relapse after CAR-T infusion is minimal residual&#xD;
      disease (MRD) which will induce CD19 negative relapse. CD20/CD22/CD10 is still expressed in&#xD;
      CD19 negative B-ALL cells which means these CD molecules may become new targets in treatment&#xD;
      of CD19 negative relapse of B-ALL. Thus sequential treatment with CD20/CD22/CD10-CART after&#xD;
      CD19-CART treatment in relapsed/refractory B-ALL will kill and eliminate CD19 negative B-ALL&#xD;
      cells and prolong the remission time.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 18, 2016</start_date>
  <completion_date type="Anticipated">March 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events that Are related to treatment</measure>
    <time_frame>2 years</time_frame>
    <description>Determine the toxicity profile of the CD19-targeted and CD20/CD22/CD10-targeted CAR-T cells with Common Toxicity Criteria for Adverse Effects (CTCAE) version 4.0.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Estimate 2 year overall survival(OS) after infusion of CD19-CART and sequential treatment</measure>
    <time_frame>2 years</time_frame>
    <description>To estimate 2 year overall survival(OS) after CD19-CART infusion and sequential treatment with Relapsed/Refractory B-ALL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimate relapse rate after infusion of CD19-CART and sequential treatment</measure>
    <time_frame>4 years</time_frame>
    <description>To estimate relapse rate after CD19-CART infusion and sequential treatment with Relapsed/Refractory B-ALL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimate 2 year progression free survival after infusion of CD19-CART and sequential treatment</measure>
    <time_frame>2 years</time_frame>
    <description>To estimate 2 year progression free survival (PFS) after CD19-CART infusion and sequential treatment with Relapsed/Refractory B-ALL</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Therapy Related Leukemia</condition>
  <arm_group>
    <arm_group_label>Sequential therapy with different CART</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sequential therapy With different CART including one kind of CD20/CD22/CD10-CART After CD19-CART therapy in CD19-negative relapse ALL patients, subjects will receive 1-5 x 10^6/Kg transduced CAR T cells at one time.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Sequential Treatment With different CART</intervention_name>
    <description>Sequential Treatment With CD20/CD22/CD10-CART After CD19-CART Treatment in Relapsed/Refractory B-ALL</description>
    <arm_group_label>Sequential therapy with different CART</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Relapsed/Refractory B-ALL patients&#xD;
&#xD;
          2. Did not achieve complete remission after 2 times of standard plan chemotherapy&#xD;
&#xD;
          3. Relapsed after first induction chemotherapy&#xD;
&#xD;
          4. Did not response to chemotherapy before HSCT or relapsed after HSCT&#xD;
&#xD;
          5. Cannot receive allo-HSCT or refuse to receive allo-HSCT&#xD;
&#xD;
          6. Relapsed after CD19-CART infusion&#xD;
&#xD;
          7. MRD monitoring confirmed positive(MRD&gt;0.01%) after CD19-CART infusion&#xD;
&#xD;
          8. Cell phenotype is CD19 negative and CD20/CD22/CD10 positive (single or combined) after&#xD;
             CD19-CART therapy&#xD;
&#xD;
          9. Estimated survival time is more than 3 months in leukemia&#xD;
&#xD;
         10. Volunteered for this clinical trail and signed a consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. MRD was negative after CD19-CART therapy&#xD;
&#xD;
          2. MRD was negative while the cell phenotype was CD19 expressed&#xD;
&#xD;
          3. Patients with severe insufficient cardiac, pulmonary and hepatorenal functions&#xD;
&#xD;
          4. Patients with severe mental illness, neurological disease or infectious disease&#xD;
&#xD;
          5. Patients with GVHD was taking immunosuppressants&#xD;
&#xD;
          6. Pregnant or lactating women&#xD;
&#xD;
          7. Patients have received other genetic therapy products&#xD;
&#xD;
          8. Transfection efficiency was less than 30%&#xD;
&#xD;
          9. Any situation may do harm to the subjects or interfere the results&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yanjie He, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Zhujiang Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yuhua Li, Ph.D</last_name>
    <phone>86-20-61643188</phone>
    <email>liyuhua2011gz@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sanfang Tu, Ph.D</last_name>
    <phone>86-20-62782322</phone>
    <email>doctortutu@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Southern Medical University Zhujiang Hospital</name>
      <address>
        <city>Guangdong</city>
        <state>Guangdong</state>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuhua Li, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>April 9, 2017</study_first_submitted>
  <study_first_submitted_qc>January 16, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 23, 2018</study_first_posted>
  <last_update_submitted>August 9, 2021</last_update_submitted>
  <last_update_submitted_qc>August 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CD19-CART</keyword>
  <keyword>CD20-CART</keyword>
  <keyword>CD10-CART</keyword>
  <keyword>CD22-CART</keyword>
  <keyword>Relapsed/Refractory B-ALL</keyword>
  <keyword>MRD</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

